Bhin et al. show that MYC activation drives resistance to mTOR inhibitors and is significantly associated with poor response to mTOR inhibition in breast cancer patients, suggesting the potential of MYC as a biomarker for predicting resistance to mTOR-targeted therapies. This evidence concerns the gene MTOR and breast cancer.